The efficacies of meropenem, a novel carbapenem, and ceftazidime, as empirical therapy of febrile neutropenic patients, were compared in a prospective, randomized clinical trial. One hundred and twelve adult patients were given meropenem 1 g tds iv for 153 episodes of fever, while 109 patients received ceftazidime 2 g tds iv for 151 episodes. All patients survived the first 3 days of therapy and, by the end of the treatment courses, 67 (44%) episodes had responded to meropenem, compared with 62 (41 %) to ceftazidime. Eighty (53%) episodes initially treated with ceftazidime and 63 (41%) episodes treated with meropenem were considered to have failed treatment because it was thought necessary to administer additional antibacterial agents; however, modifications were made twice as often because of fever that persisted beyond 2-3 days than because of obvious causes of failure such as persistent infection. Three patients in the ceftazidime group and five in the meropenem group died. Meropenem was well tolerated, with no reports of nausea or toxicity to the central nervous system. Although ceftazidime was shown in the present study to be as effective as meropenem, the broader spectrum of activity of meropenem against Gram-positive cocci suggests that it might be more appropriate as empirical therapy of febrile neutropenic patients who are at high risk of acquiring infections caused by these bacteria.
Introduction
Ceftazidime has been used as monotherapy for febrile neutropenic patients for more than a decade (De Pauw et al., 1985; Pizzo et a l., 1986; Sanders, Powe & Moore, 1991) and has been shown to be as effective as standard regimens (De Pauw et a l 1994) . However, the addition of other antibiotics is frequently necessary in order to provide optimal cover for coagulase-negative staphylococci, which are usually associated with central venous catheters (Raad & Bodey, 1992) , and viridans streptococci which gain access to the bloodstream as the result of mucositis caused by intensive chemotherapy and which are occasionally associated with shock and the adult respiratory distress syndrome (ARDS) (Cohen et al., 1983; Villablanca et al,, 1990) .
Carbapenems exhibit in-vitro activities against aerobic Gram-negative bacilli (AGNB) which are similar to those of the cephalosporins, but have greater activities against Gram-positive bacteria (Edwards et a l , 1989) . These agents might therefore be superior to cephalosporins as initial therapy of febrile neutropenic patients, owing to the marked increase in the incidence of infections caused by Gram-positive organisms that has resulted from recent changes in clinical practice (EORTC International Antimicrobial Therapy Cooperative Group, 1990) . However, the administration of imipenem/cilastatin, the first carbapenem to become available for clinical use, is frequently associated with nausea and vomiting in neutropenic patients (Winston et a l, 1991; Leyland et a l , 1992) and can induce seizures (Bodey et a l., 1987) . Meropenem, a novel carbapenem, might be a more acceptable alternative since it retains the broad spectrum of activity of imipenem (Donnelly et a l , 1992a ) but does not cause nausea and vomiting and is apparently free of central nervous system toxicity (Donnelly et a l , 1992ft) . The aim of this unblinded, prospective, multicentre trial was to compare the efficacy and tolerability of meropenem with that of ceftazidime as empirical therapy of febrile episodes in neutropenic adult patients.
Patients and methods

Patients
Adult patients receiving intensive chemotherapy for haematological malignancies whose neutrophil counts had fallen, or were expected to fall within the next 48 h, to <0-5 x 109/L and who were considered febrile, having developed axillary tempera tures of >38*5°C, were eligible for inclusion into the trial. Patients were excluded for one or more of the following reasons; allergy to penicillins or cephalosporins; a serum creatinine concentration of > 265 pmol/L; or the previous administration of parenteral antibiotic therapy during the same neutropenic episode. The study was approved by the Ethics Committee in each participating centre and consent was obtained from all patients.
Treatment
Patients were randomized to receive brief intravenous infusions of either ceftazidime (2 g tds) or meropenem (1 g tds). Allocation to one or the other regimen was achieved by an investigator opening the next in a sequence of sealed envelopes containing numbers generated by a computer in each centre. Treatment was initiated immediately after completion of a comprehensive physical examination and after samples of blood and other appropriate specimens (determined according to clinical signs) had been obtained for culture. The use of prophylactic antibacterial agents was prohibited for the duration of the trial.
Therapy was continued until a patient was free of all signs and symptoms of infection for at least 2 days when the neutrophil count exceeded 05 x 109/L or for 5 consecutive days when the count remained below 0-5 x 109/L. Ceftazidime or meropenem was substituted with an alternative agent if a patient experienced a severe adverse event. One or more additional antimicrobials were given for the following reasons: if a pathogen which was resistant to the empirical regimen was isolated; if a patient was not responding to treatment, as demonstrated by a marked deterioration in the clinical condition, persistent bacteraemia or pyrexia persisting for > 72 h; if there was recurrence of fever; or if, following resolution of the original infection, a patient developed another clinically or microbiologically defined infection.
Investigations
Patients were examined daily, routine haematological investigations were carried out daily or on alternate days and routine liver and renal function tests were performed at least once weekly. Additional blood cultures were obtained on the second or third day of treatment and whenever there was recurrence of fever. Chest X-rays and invasive diagnostic procedures such as bronchoalveolar lavage were performed when indicated.
Bacteriological isolates were identified according to standard techniques and antibiotic susceptibilities were determined by the disc diffusion method; an organism was considered resistant to ceftazidime if the inhibitory zone diameter was <14 mm (National Committee for Clinical Laboratory Standards, 1990) and to meropenem when the diameter was <10 mm (Zeneca Pharmaceuticals, data on file).
Classification o f infection
Bacteraemia was defined as the isolation of a recognized pathogen from at least one set of blood cultures or of the same strain of a coagulase-negative staphylococcus or a Corynebacterium sp. from at least two sets of blood cultures obtained by separate venepunctures. A putative site of infection was classified as a clinically defined infection unless confirmed by the isolation of a recognized pathogen, either from the site itself or from blood cultures, in which case it was classified as a microbiologically defined infection. All other episodes were regarded as fevers of unknown origin. Death was attributed to infection only when it occurred as a direct consequence and a microbiologically defined infection that developed during an initial course of treatment was classified as a superinfection.
Assessment o f response to therapy
Each treatment episode was assessed according to guidelines proposed by the Immunocompromised Host Society (Immunocompromised Host Society Consensus Panel, 1990) . Briefly, therapy was regarded as having been successful if all signs and symptoms of infection resolved without modification of the initial empirical regimen. If it was necessary for an antifungal or antiviral agent to be added to the initial regimen, the episode was considered to have been a response to a modified regimen, whereas the addition of one or more other antibacterial agents or death directly attributable to infection constituted failure. If treatment was discontinued for reasons unrelated to infection, such as allergy or sudden death due to haemorrhage, the episode was considered unevaluable for efficacy. All patients were included in the assessment of safety and tolerance.
The bacteriological responses of microbiologically defined infectious episodes to the study regimens were assessed only if follow-up cultures had been obtained before the initial treatment was either modified or discontinued. The original pathogen was considered to have been eradicated if it was not isolated from a follow-up culture, while recovery of this organism from a follow-up culture was classified as persistence. 
Statistical analysis
Success rates were expressed as odds ratios, where unity indicated equivalence, a value > 1 suggested superiority of meropenem and a value < 1 denoted the superiority of ceftazidime. Lack of statistical significance was inferred when the 95% confidence intervals (Cl) for the odds ratios encompassed unity, although formal analysis was also undertaken with the Chi-square test without a correction factor.
Results
Patients
A total of 338 febrile episodes in 248 neutropenic patients were treated with either ceftazidime (168 episodes) or meropenem (170 episodes). Thirty-four episodes were subsequently excluded from the analysis of efficacy for the following reasons: failure to fulfil the entry criteria (12 episodes and 15 episodes treated with ceftazidime and meropenem respectively); fever shown not to be caused by a bacterial pathogen (four episodes treated with ceftazidime and two with meropenem); and non-evaluability (one patient in the ceftazidime group who died of haemorrhage on the ninth treatment day after all signs and symptoms of infection had resolved). Therefore, 151 and 153 episodes treated with ceftazidime and meropenem respectively were available for analysis, The patients in the two groups were comparable with respect to age, sex, underlying disease, degree of neutropenia and the use and type of oral prophylaxis and central venous lines (Table I) .
Details of febrile episodes
The two groups were similar in terms of the classification of febrile episodes (Table II) . Microbiologically and clinically defined infections together accounted for 70% of Specimens were obtained in respect of only 25 of 51 (49%) episodes of localized infection treated with ceftazidime and from only 27 of 59 (46%) of those treated with meropenem; a pathogen was isolated in only six and eight of these episodes respectively. Five of the ceftazidime-treated episodes were catheter exit site infections, caused by coagulase-negative staphylococci (together with a strain of C. jeikeium in one patient) (four cases) and Staphylococcus aureus (one case); two of the coagulase-negative staphylococci were resistant to ceftazidime. The sixth episode in the ceftazidime group was an infection of the oral mucosa caused by herpes simplex. Five of the episodes treated with meropenem were also catheter exit site infections, caused by strains of coagulase-negative staphylococci (three cases), Enterobacter cloacae (one) and both S. aureus and S . maltophilia (one) . The other localized infections in the meropenem group included one case each of a urinary tract infection caused by Escherichia coli, necrotising pharyngitis caused by Pseudomonas aeruginosa and a lower respiratory tract infection in a patient from whose sputum Aspergillus terreus was isolated. One strain of Staphylococcus epidermidis and the S . maltophilia strain were resistant to meropenem.
Clinical response rates
Ceftazidime was administered for a mean of 11 *3 days and meropenem for a mean of 10-7 days. The rates of defervescence were also similar for the two groups ( Figure 1) ; it was noteworthy that approximately 75% of patients were still febrile after 3 days of therapy.
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Mer op en em Study Group Successful response. O f the 151 evaluable episodes treated with ceftazidime and the 153 treated with meropenem, 62 (41%) and 67 (44%) respectively responded to the initial r e g i m e n s without modifications (odds ratio, 1.1; 95% Cl, 0*71-1 -76) (Table IV) . A higher percentage of the bacteraemic episodes without localized infection which were treated with meropenem were classified as successes, compared with those treated with ceftazidime (47% vs 31 %), but the difference was not statistically significant. The response rates for the other categories of febrile episode were similar for both groups.
Response to a modified regimen. Antifungal agents were administered as first modifications of the empirical regimens in four episodes treated with ceftazidime and in ten treated with meropenem. Similarly, acyclovir was prescribed for two and eight episodes in the ceftazidime and meropenem groups respectively. A further modification of therapy was required for three of the six episodes initially treated with ceftazidime (two episodes treated with vancomycin and one with amphotericin B (AMB)) and for three of the ten episodes initially treated with meropenem (two episodes treated with AMB and one with penicillin).
Failure of therapy. Overall, 83 (55%) of ceftazidime-treated episodes and 68 (44%) of meropenem-treated episodes were classified as treatment failures.
Treatment was considered to have failed because at least one other antibacterial agent was added to the initial regimen in 80 (53%) of episodes treated with ceftazidime and in 63 (41%) of episodes treated with meropenem (P < 0*001) (Table IV) . Treatment was modified for both clinically defined and bacteraemic episodes (without localized infections) approximately twice as often in the ceftazidime group as in the meropenem group, but there were no significant differences between the groups in terms of the frequencies of modification for the other categories of febrile episode. The reasons for the first modification were similar in each group (Table V) . Persistent pyrexia was the principal reason, accounting for 71 % and 79% of first modifications in the ceftazidime and meropenem groups respectively, although fever had persisted for <72h in approximately 60% of cases. Persistent bacteraemia and resistance of a pathogen to the empirical regimen together led to modifications in 17% of episodes treated with ceftazidime and in 8% treated with meropenem; strains of S. epidermidis accounted for seven of the 13 pathogens in the former group and for three of the five in the latter group, Therapy was changed because of recurrence of either fever or infection in 13% of episodes in both groups. The most frequently prescribed antibiotics were the glycopeptides which comprised approximately 60% of first modifications in each group (Table VI) . Treatment with these agents was initiated a mean of 5-1 days after starting therapy with ceftazidime and a mean of 4-8 days after starting therapy with meropenem. Although penicillin was administered more often for episodes initially treated with ceftazidime than for those treated with meropenem, the other second-line antibiotics were given equally frequently in both treatment groups. Two or more additional agents were prescribed concurrently in 13 and ten episodes treated with ceftazidime and meropenem respectively. Further modifications were required for 47 (59%) of episodes where ceftazidime was administered initially and for 32 (51%) of those where meropenem was given. Failure of therapy was attributed to death from infection in three (2%) patients treated with ceftazidime and in five (3 %) given meropenem. Two of the patients in the ceftazidime group had bacteraemias caused by susceptible strains of P. aeruginosa. One of these died of pneumonia on the fourth day of treatment, despite eradication of the pathogen from the bloodstream, and the other of multi-organ failure on the fifth day of treatment, 1 day after tobramycin had been added to the regimen; no further specimens were obtained for culture from the latter patient. The third patient developed A R D S and died 8 days after beginning therapy with ceftazidime, Strains of E.faecalis and S. epidermidis were isolated from this patient's blood cultures, but their susceptibilities were not recorded and the organisms persisted until penicillin and vancomycin had been administered. Three patients died of pneumonia 8, 9 and 20 days respectively after beginning therapy with meropenem. Although blood cultures from the first of these patients were sterile, he was still given vancomycin and erythromycin. The second patient had a bacteraemia caused by a strain of S. epidermidis which was eradicated before a glycopeptide was given, despite being resistant to meropenem; this patient had also received AMB. Strains of S. epidermidis and Streptococcus mitis were recovered from the blood cultures of a third (100) 68 (100) "T he to ta l n u m b e r o f agents exceeds the n u m b e r o f episodes as m ore th a n one agent w as given as first m o d ific a tio n in 13 a n d ten episodes treated in itia lly w ith c e fta zid im e a n d m e ro p e n e m respectively. patient. Both isolates were susceptible to meropenem and were eradicated before treatment with vancomycin was initiated. This patient had also been given fluconazole and ÀMB for a suspected fungal infection, A fourth patient died of ARDS after 23 days of treatment with meropenem for bacteraemia caused by strains of 5. mitis and S. epidermidis. The antimicrobial susceptibilities of these organisms were not determined, but both were eradicated before penicillin and teicoplanin were added to the regimen. This patient was subsequently given AMB, acyclovir and erythromycin. The fifth patient died of peritonitis following bowel perforation 17 days after beginning treatment for bacteraemia caused by a susceptible strain of S. epidermidis which was eradicated before teicoplanin was administered; this patient also received metronidazole and gentamicin.
Modifications of therapy
Overall, therapy was modified with equal frequencies in the two groups ( Figure 2) ; the percentages of patients receiving either meropenem or ceftazidime alone declined at a similar rate. Modifications were made by the third day in 14 (9%) episodes treated with ceftazidime and in 12 (8%) treated with meropenem; in all but two episodes in each group, the newly-administered drugs were antibacterials. By the end of the treatment courses, each of the individual agents had been prescribed with the same frequencies in the two (8) 10 (7) treatment groups (Table VII) , the glycopeptides having been administered approximately twice as often as the next most frequently prescribed group of drugs.
Bacteriological response rates
Overall, 81% and 71% of bacteraemic episodes were caused by isolates that were susceptible to meropenem and ceftazidime respectively. Fewer pathogens were eradicated by ceftazidime than by meropenem (P < 0-05) ( Table V III) . While all AGNB were eradicated by meropenem, the Achromobacter sp., Flavobacterium sp. and Serratia marcescens strains were eradicated from patients receiving ceftazidime only after the administration of other agents. Superinfections developed in 14 patients treated with ceftazidime and in 17 given meropenem.
Adverse events
Rashes were reported during or after six (4%) episodes treated with ceftazidime, compared with only two (1%) treated with meropenem. Transient elevations of liver transaminase concentrations were detected in one and three patients in the ceftazidime and meropenem groups respectively. Six patients with previous histories of seizures and one with a focal central nervous system disease were treated with meropenem without experiencing adverse effects.
Discussion
The rapid initiation of broad spectrum antibacterial therapy has had a profound impact on the incidence of mortality attributable to infection in the febrile, neutropenic patient (Schimpff et a l., 1971) . While this practice has been adopted almost universally, it was initially assumed that only combination therapy was suitable for high-risk patients, such as those with acute leukaemia whose treatment induced severe and prolonged neutropenia (Hughes et a l., 1990 ), More recently, however, there has been a number of studies which have shown that monotherapy is equally effective (Pizzo et a L , 1986; Winston et a l., 1991; Leyland et a l., 1992; De Pauw et a l 1994) and is associated with a lower incidence of toxicity. These results generated considerable controversy, those opposing monotherapy being hesitant to accept it as an alternative to more standard regimens, principally because the early studies lacked statistical power (Hughes et ah, 1990) . A similar criticism might also be applied to the present study which involved 311 febrile episodes but, since all patients survived the first 3 days of treatment (the true empirical period) and 75% of them were profoundly neutropenic, the results suggest that empirical therapy with a single agent at the very least prevents early death due to infection. Moreover, the majority of patients had received intensive chemotherapy for acute leukaemia, and yet, 96% survived 297 febrile neutropenic episodes, survival rates which compare favourably with those reported for combination therapy (Pizzo et al., 1986; EORTC International Antimicrobial Therapy Cooperative Group, 1987; De Pauw et a l., 1994) .
The regimens evaluated in this study were shown to be equally effective; even the rates of defervescence were similar. Consistent with current trends, the ratio of Gram-positive to Gram-negative bacterial pathogens was almost 4:1. The predominance of coagulase-negative staphylococci as blood culture isolates reflects the extensive use of central venous lines in this patient population and is the most likely explanation for the 6/10 (60%)
Meropenem Study Group widespread use of glycopeptides as second-line treatment since ceftazidime is perceived as having poor activity against Gram-positive bacteria. Meropenem, on the other hand, is more active in vitro against these organisms, and was therefore expected to be more effective as treatment for infections caused by them. Surprisingly then, there was little difference between the two groups in terms of the use of vancomycin and teicoplanin. Moreover, a third of patient episodes treated with meropenem were also treated with a glycopeptide, probably because of the tendency to supplement empirical regimens when fever persists, irrespective of the microbiological findings. Indeed, in this study, persistent fever was the most common reason for administering a glycopeptide, although Gram-positive bacteria persisted in only 17 of the 177 episodes in which such a drug was given. While the percentage of isolates resistant to ceftazidime was greater than that resistant to meropenem, as many as two-thirds of the strains were susceptible to this agent, confirming that modifications were usually made on clinical rather than microbiological grounds. There also seemed to be a tendency to prescribe a glycopeptide as a first modification because the risks of infection caused by Gram-positive bacteria were perceived as being high. Giving vancomycin or teicoplanin as second-line treatment for a fever lasting less than 4 days might therefore have obscured a genuine difference between the treatment groups, since the average duration of fever in neutropenic patients who have responded to initial therapy has been reported to be between 4 and 5 days (Novakova, Donnelly & De Pauw, 1991) . There are compelling reasons, therefore, to restrict the glycopeptides to the treatment of patients with persistent infections, instead of administering them empirically, unless the anticipated incidences of morbidity and mortality attributable to infections caused by these organisms are exceptionally high (Donnelly et a l 1993) . One could argue that combining meropenem with another agent with activity against Gram-positive bacteria is superfluous, except, perhaps, where methicillin-resistant strains of staphylococci are implicated. In support of this view, the administration of a glycopeptide in the present study was regarded as necessary in only 50% of the febrile episodes caused by coagulase-negative staphylococci which were initially treated with meropenem, compared with almost all of those initially treated with ceftazidime. Overall, only a minority of changes of therapy were made on objectively verifiable grounds, such as clinical deterioration, persistent bacteraemia, relapse or a new infectious episode. Rather, treatment was altered with equal frequencies in both groups, principally for persistent fever and with a similar range of antimicrobials. Moreover, in the majority of episodes in which initial treatment was modified, there was also a second modification. Subjective criteria were usually employed in both cases, suggesting that these decisions were made against a background of considerable uncertainty. A tendency to modify therapy according to subjective criteria was also noted in a recent study carried out by the EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada Clinical Trials Group (1991) . This is a source of concern as it has been shown that, far from improving outcome, the liberal and inappropriate use of antibiotics actually increases both costs and the risks of superinfection (O'Hanley et aL, 1989) .
As the assessment of outcome depends critically on how failure of therapy is defined, the criteria for modifying treatment should be specified beforehand; these criteria might also define persistent fever as lasting for at least 4 or 5 days (Donnelly et al., 1993) , thereby acknowledging that a continuing fever does not necessarily mean that the original infection has not responded to treatment.
It is interesting to note that the response rates in this study for episodes of fever of unknown origin were much higher than those for microbiologically and clinically defined infections, irrespective of whether or not an aetiology had been determined. Clearly, physicians are inclined to modify treatment more frequently when dealing with such infections, although prescribing additional antibacterials is likely to be futile as more infections which are only clinically defined, particularly those involving the lungs, are caused by fungi than by bacteria (Commers, Robichaud & Pizzo, 1984) . A systemically active antifungal agent was, in fact, administered to almost one in five patients in each group and was the most popular choice for the first modification of therapy in patients who had failed to respond to meropenem, the assumption being that Gram-positive bacteria were adequately covered, at least initially, by this drug. On the other hand, in the ceftazidime group, there was a tendency to add either vancomycin or teicoplanin for bacteraemias caused by coaguiase-negative staphylococci, in the belief that the cephalosporin possessed less than optimal activity against these pathogens. The only means of overcoming this unwi tting bias would have been to blind the observers, but this was impossible at the time because of the characteristically unpleasant odour of ceftazidime. In reality, there appeared to be only minimal bias, as demonstrated by the observation that the indications for modification and the drugs used for this purpose were comparable in each group, suggesting that the responses of the clinicians would not have been significantly different had they been unaware of the empirical regimens to which the patients had been assigned.
Meropenem also fulfilled our expectations in terms of safety. Neither nausea nor seizures were observed, even in the six patients with histories of central nervous system disease. Hepatic and renal toxicities were rare and the incidence of skin rash was lower than that observed with ceftazidime. Meropenem also appears to be associated with fewer adverse events than imipenem/cilastatin (Winston et a l., 1991; Leyland et a l , 1992) , whereas the efficacies of the two drugs appear similar (Winston et al., 1991; Leyland et a l, 1992) . It was also encouraging to note that all four episodes of infection caused by strains of E. cloacae responded to meropenem, particularly as relapses, resulting from derepression ofchromosomally-mediated p-lactamases, have been reported following the treatment of such infections with cephalosporins (Johnson & Ramphal, 1990 ).
In conclusion, meropenem has been shown in the present study to be both effective and well-tolerated treatment of febrile neutropenic patients and, given the high incidences of infections caused by coagulase-negative staphylococci and viridans streptococci, it appears to meet the current requirements of empirical antimicrobial therapy in this clinical setting.
